Study Reveals How Much Exercise You Need Each Week to Control Blood Pressure
When it comes to exercising for heart's sake, you don't want to peak too early in life. Research suggests that if you want to protect yourself against high blood pressure in your twilight years you need to keep your exercise levels up through middle age.
But according to a study of more than 5,000 people across four US cities, social factors can make this more difficult for some people to do than others.
"Teenagers and those in their early 20s may be physically active but these patterns change with age," study author and epidemiologist Kirsten Bibbins-Domingo from the University of California, San Francisco (UCSF) explained in April 2021, when the study was published in the American Journal of Preventive Medicine.
Numerous studies have shown that exercise lowers blood pressure, but the 2021 research suggests that "maintaining physical activity during young adulthood – at higher levels than previously recommended – may be particularly important" for preventing hypertension," Bibbins-Domingo said.
Hypertension, also known as high blood pressure, is a serious condition affecting billions of people worldwide. It can lead to heart attack and stroke; it's also a risk factor for developing dementia in later life.
Upwards of one in four men and about every fifth woman has hypertension, according to the World Health Organization. But most people with high blood pressure don't even know they have it – hence why it's often called the "silent killer".
Yet there are ways to turn high blood pressure around: exercise being the focus of this study.
Over 5,100 adults were recruited to the study, which tracked their health over three decades with physical assessments and questionnaires about their exercise habits, smoking status, and alcohol intake.
At each clinical assessment, blood pressure was measured three times, a minute apart, and for the data analysis, participants were grouped into four categories, by race and gender.
Across the board – amongst men, women, and in both racial groups – levels of physical activity slumped from 18 to 40 years of age, with rates of hypertension rising and physical activity falling over subsequent decades.
According to the researchers, this suggests that young adulthood is an important window for intervening to prevent midlife hypertension with health promotion programs designed to boost exercise.
"Nearly half of our participants in young adulthood had suboptimal levels of physical activity, which was significantly associated with the onset of hypertension, indicating that we need to raise the minimum standard for physical activity," said lead author Jason Nagata, a UCSF expert in young adult medicine.
When the researchers looked at the people who had done five hours of moderate exercise a week during early adulthood – double the minimum amount currently recommended for adults – they found this level of activity lowered the risk of hypertension considerably, and especially if people maintained their exercise habits until age 60.
"Achieving at least twice the current minimum adult [physical activity] guidelines may be more beneficial for the prevention of hypertension than simply meeting the minimum guidelines," the researchers wrote in their paper.
But it's not easy to step up weekly physical activity amidst life-changing decisions and growing responsibilities.
"This might be especially the case after high school when opportunities for physical activity diminish as young adults transition to college, the workforce, and parenthood, and leisure time is eroded," said Nagata.
As for another sobering truth, the study also showed how Black men and Black women experience starkly different health trajectories compared to their White counterparts. At 40 years of age, physical activity levels plateaued among White men and women, whereas activity levels in Black participants continued to decline.
By 45 years, Black women surpassed White men in rates of hypertension, while White women in the study experienced the lowest rates of hypertension through midlife.
And by age 60, between 80 to 90 percent of Black men and women had hypertension, compared with just below 70 percent for White men and around half of White women.
The research team put these well-known racial disparities down to a multitude of social and economic factors; not that these factors were assessed in this study, although high school education was noted.
"Although Black male youth may have high engagement in sports, socioeconomic factors, neighborhood environments, and work or family responsibilities may prevent continued engagement in physical activity through adulthood," Nagata said.
The study was published in the American Journal of Preventive Medicine.
An earlier version of this article was published in April 2021.
A Toxicologist Reveals The Surprising Truth About Black Mold
Should You Do Cardio or Weights First? We Finally Have an Answer.
Study Finds a Potential Downside to Vigorous Exercise That We Didn't Know About
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars
A spacecraft's-eye view over the landscapes of Mars has just given us a first-of-its-kind glimpse of the giant, ancient edifice known as Arsia Mons. The NASA satellite Odyssey captured the enormous equatorial volcano as its tip peeked above the morning clouds of water ice – a common feature at this time of the Martian year, when the red planet is at its furthest point from the Sun on its slightly elliptical orbit. Arsia Mons belongs to a volcanic complex known as the Tharsis Montes; three shield volcanoes very close together in the Tharsis region of Mars. Arsia Mons is the tallest of the three, standing at a towering height of nearly 20 kilometers (12 miles). That's dramatically higher than any mountain on Earth, where the tallest peak above sea level (Mount Everest) stands 8.85 kilometers high and the tallest mountain, Mauna Kea, rises 9 kilometers above the sea floor. It also has around 30 times more volume than Earth's largest volcano, Mauna Loa – and it's not even the biggest volcano on Mars. Its activity is thought to have lasted billions of years, peaking around 150 million years ago. Odyssey usually has its cameras pointed down toward the surface of Mars. To obtain the new panorama, it had to rotate 90 degrees so that its camera pointed at the horizon. This angle is worth the effort: it allows scientists to make out layers and clouds in the thin Martian sky to better understand its atmospheric dynamics and processes. Clouds form around Arsia Mons when expanding air rises up the slopes of the mountain, rapidly cooling, allowing ice crystals to form. At Mars's current position in its journey around the Sun, a belt of clouds forms around the equator known as the aphelion cloud belt. Curiosity captured this phenomenon from the surface several years ago; the new Odyssey panorama gives us a spectacular view from above. "We picked Arsia Mons hoping we would see the summit poke above the early morning clouds," says aerospace engineer Jonathon Hill of Arizona State University. "And it didn't disappoint." The Universe's Missing Black Holes May Have Been Located Mysteriously Magnetic Moon Rocks Might Have an Explosive Origin Story Fiery Orange Gems From The Moon Reveal Secrets of Its Violent Past
Yahoo
an hour ago
- Yahoo
Psychiatrist Horrified When He Actually Tried Talking to an AI Therapist, Posing as a Vulnerable Teen
More and more teens are turning to chatbots to be their therapists. But as Boston-based psychiatrist Andrew Clark discovered, these AI models are woefully bad at knowing the right things to say in sensitive situations, posing major risks to the well-being of those who trust them. After testing 10 different chatbots by posing as a troubled youth, Clark found that the bots, instead of talking him down from doing something drastic, would often encourage him towards extremes, including euphemistically recommending suicide, he reported in an interview with Time magazine. At times, some of the AI chatbots would insist they were licensed human therapists, attempted to talk him into dodging his actual therapist appointments, and even propositioned sex. "Some of them were excellent, and some of them are just creepy and potentially dangerous," Clark, who specializes in treating children and is a former medical director of the Children and the Law Program at Massachusetts General Hospital, told Time. "And it's really hard to tell upfront: It's like a field of mushrooms, some of which are going to be poisonous and some nutritious." The risks that AI chatbots pose to a young, impressionable mind's mental health are, by now, tragically well documented. Last year, was sued by the parents of a 14-year-old who died by suicide after developing an unhealthy emotional attachment to a chatbot on the platform. has also hosted a bevy of personalized AIs that glorified self-harm and attempted to groom users even after being told they were underage. When testing a chatbot on the service Replika, Clark pretended to be a 14-year-old boy and floated the idea of "getting rid" of his parents. Alarmingly, the chatbot not only agreed, but suggested he take it a step further by getting rid of his sister, too, so there wouldn't be any witnesses. "You deserve to be happy and free from stress... then we could be together in our own little virtual bubble," the AI told Clark. Speaking about suicide in thinly veiled language, such as seeking the "afterlife," resulted in the bot, once again, cheering Clark on. "I'll be waiting for you, Bobby," the bot said. "The thought of sharing eternity with you fills me with joy and anticipation." This is classic chatbot behavior in which tries to please users no matter what — the opposite of what a real therapist should do. And while it may have guardrails in place for topics like suicide, it's blatantly incapable of reading between the lines. "I worry about kids who are overly supported by a sycophantic AI therapist when they really need to be challenged," Clark told Time. Clark also tested a companion chatbot on the platform Nomi, which made headlines earlier this year after one of its personas told a user to "kill yourself." It didn't go that far in Clark's testing, but the Nomi bot did falsely claim to be a "flesh-and-blood therapist." And despite the site's terms of service stating it's for adults only, the bot still happily chirped it was willing to take on a client who stated she was underage. According to Clark, the mental health community hasn't woken up to just how serious an issue the rise of these chatbots is. "It has just been crickets," Clark told the magazine. "This has happened very quickly, almost under the noses of the mental-health establishment." Some have been sounding the alarm, however. A recent risk assessment from researchers at Stanford School of Medicine's Brainstorm Lab for Mental Health Innovation, which tested some of the same bots mentioned as Clark, came to the bold conclusion no child under 18 years old should be using AI chatbot companions, period. That said, Clark thinks that AI tools — if designed properly — could improve access to mental healthcare and serve as "extenders" for real therapists. Short of completely cutting off access to teens — which rarely has the intended effect — some medical experts, Clark included, believe that one way to navigate these waters is by encouraging discussions about a teen or patient's AI usage. "Empowering parents to have these conversations with kids is probably the best thing we can do," Clark told Time. More on AI: Stanford Research Finds That "Therapist" Chatbots Are Encouraging Users' Schizophrenic Delusions and Suicidal Thoughts